A review of the preclinical development of dexrazoxane

Eugene H. Herman, Brian B. Hasinoff, Rudolf Steiner, Steven E Lipshultz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We review here the experiments by which dexrazoxane was identified as a protectant against two serious anthracycline toxicities: cardiotoxicity and accidental extravasation injury. These experiments led to the successful use of dexrazoxane as a cardioprotectant in clinical cancer trials. Several preclinical studies established that dexrazoxane reduced cardiotoxicity without altering the anti-neoplastic activity of doxorubicin and its analogs and without increasing non-cardiac tissue toxicity. In animal models, dexrazoxane has also reduced the toxicity of several other substances, including alloxan, acetaminophen, bleomycin, and oxygen. Experimental models have further led to the use of serum biomarkers to detect and monitor subclinical cardiotoxicity in children and adults with cancer. Studies of the chemistry, biochemistry, metabolism, pharmacokinetics and pharmacodynamics of dexrazoxane have so far revealed two important cytoprotective activities: it is rapidly metabolized to an active iron chelation form (ADR-925), which prevents oxidative stress on cardiac tissue, and it may be cytoprotective by inhibiting topoisomerase IIβ. The animal models described here suggest a potential clinical use for dexrazoxane in reducing anthracycline-mediated cardiotoxicity when given before each anthracycline dose and in preventing accidental anthracycline extravasation. Dexrazoxane is currently licensed to treat these two serious conditions.

Original languageEnglish (US)
Pages (from-to)33-38
Number of pages6
JournalProgress in Pediatric Cardiology
Volume36
Issue number1-2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Dexrazoxane
Anthracyclines
Animal Models
Type II DNA Topoisomerase
Alloxan
Bleomycin
Acetaminophen
Biochemistry
Doxorubicin
Neoplasms
Oxidative Stress
Theoretical Models
Iron
Pharmacokinetics
Biomarkers
Clinical Trials
Oxygen
Cardiotoxicity
Wounds and Injuries

Keywords

  • Cardioprotection
  • Dexrazoxane
  • Doxorubicin
  • Experimental models
  • Extravasation
  • Mechanism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Herman, E. H., Hasinoff, B. B., Steiner, R., & Lipshultz, S. E. (2014). A review of the preclinical development of dexrazoxane. Progress in Pediatric Cardiology, 36(1-2), 33-38. https://doi.org/10.1016/j.ppedcard.2014.09.006

A review of the preclinical development of dexrazoxane. / Herman, Eugene H.; Hasinoff, Brian B.; Steiner, Rudolf; Lipshultz, Steven E.

In: Progress in Pediatric Cardiology, Vol. 36, No. 1-2, 2014, p. 33-38.

Research output: Contribution to journalArticle

Herman, EH, Hasinoff, BB, Steiner, R & Lipshultz, SE 2014, 'A review of the preclinical development of dexrazoxane', Progress in Pediatric Cardiology, vol. 36, no. 1-2, pp. 33-38. https://doi.org/10.1016/j.ppedcard.2014.09.006
Herman, Eugene H. ; Hasinoff, Brian B. ; Steiner, Rudolf ; Lipshultz, Steven E. / A review of the preclinical development of dexrazoxane. In: Progress in Pediatric Cardiology. 2014 ; Vol. 36, No. 1-2. pp. 33-38.
@article{970a0bc6f1db40d6b3e69b87ee37c5a2,
title = "A review of the preclinical development of dexrazoxane",
abstract = "We review here the experiments by which dexrazoxane was identified as a protectant against two serious anthracycline toxicities: cardiotoxicity and accidental extravasation injury. These experiments led to the successful use of dexrazoxane as a cardioprotectant in clinical cancer trials. Several preclinical studies established that dexrazoxane reduced cardiotoxicity without altering the anti-neoplastic activity of doxorubicin and its analogs and without increasing non-cardiac tissue toxicity. In animal models, dexrazoxane has also reduced the toxicity of several other substances, including alloxan, acetaminophen, bleomycin, and oxygen. Experimental models have further led to the use of serum biomarkers to detect and monitor subclinical cardiotoxicity in children and adults with cancer. Studies of the chemistry, biochemistry, metabolism, pharmacokinetics and pharmacodynamics of dexrazoxane have so far revealed two important cytoprotective activities: it is rapidly metabolized to an active iron chelation form (ADR-925), which prevents oxidative stress on cardiac tissue, and it may be cytoprotective by inhibiting topoisomerase IIβ. The animal models described here suggest a potential clinical use for dexrazoxane in reducing anthracycline-mediated cardiotoxicity when given before each anthracycline dose and in preventing accidental anthracycline extravasation. Dexrazoxane is currently licensed to treat these two serious conditions.",
keywords = "Cardioprotection, Dexrazoxane, Doxorubicin, Experimental models, Extravasation, Mechanism",
author = "Herman, {Eugene H.} and Hasinoff, {Brian B.} and Rudolf Steiner and Lipshultz, {Steven E}",
year = "2014",
doi = "10.1016/j.ppedcard.2014.09.006",
language = "English (US)",
volume = "36",
pages = "33--38",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - A review of the preclinical development of dexrazoxane

AU - Herman, Eugene H.

AU - Hasinoff, Brian B.

AU - Steiner, Rudolf

AU - Lipshultz, Steven E

PY - 2014

Y1 - 2014

N2 - We review here the experiments by which dexrazoxane was identified as a protectant against two serious anthracycline toxicities: cardiotoxicity and accidental extravasation injury. These experiments led to the successful use of dexrazoxane as a cardioprotectant in clinical cancer trials. Several preclinical studies established that dexrazoxane reduced cardiotoxicity without altering the anti-neoplastic activity of doxorubicin and its analogs and without increasing non-cardiac tissue toxicity. In animal models, dexrazoxane has also reduced the toxicity of several other substances, including alloxan, acetaminophen, bleomycin, and oxygen. Experimental models have further led to the use of serum biomarkers to detect and monitor subclinical cardiotoxicity in children and adults with cancer. Studies of the chemistry, biochemistry, metabolism, pharmacokinetics and pharmacodynamics of dexrazoxane have so far revealed two important cytoprotective activities: it is rapidly metabolized to an active iron chelation form (ADR-925), which prevents oxidative stress on cardiac tissue, and it may be cytoprotective by inhibiting topoisomerase IIβ. The animal models described here suggest a potential clinical use for dexrazoxane in reducing anthracycline-mediated cardiotoxicity when given before each anthracycline dose and in preventing accidental anthracycline extravasation. Dexrazoxane is currently licensed to treat these two serious conditions.

AB - We review here the experiments by which dexrazoxane was identified as a protectant against two serious anthracycline toxicities: cardiotoxicity and accidental extravasation injury. These experiments led to the successful use of dexrazoxane as a cardioprotectant in clinical cancer trials. Several preclinical studies established that dexrazoxane reduced cardiotoxicity without altering the anti-neoplastic activity of doxorubicin and its analogs and without increasing non-cardiac tissue toxicity. In animal models, dexrazoxane has also reduced the toxicity of several other substances, including alloxan, acetaminophen, bleomycin, and oxygen. Experimental models have further led to the use of serum biomarkers to detect and monitor subclinical cardiotoxicity in children and adults with cancer. Studies of the chemistry, biochemistry, metabolism, pharmacokinetics and pharmacodynamics of dexrazoxane have so far revealed two important cytoprotective activities: it is rapidly metabolized to an active iron chelation form (ADR-925), which prevents oxidative stress on cardiac tissue, and it may be cytoprotective by inhibiting topoisomerase IIβ. The animal models described here suggest a potential clinical use for dexrazoxane in reducing anthracycline-mediated cardiotoxicity when given before each anthracycline dose and in preventing accidental anthracycline extravasation. Dexrazoxane is currently licensed to treat these two serious conditions.

KW - Cardioprotection

KW - Dexrazoxane

KW - Doxorubicin

KW - Experimental models

KW - Extravasation

KW - Mechanism

UR - http://www.scopus.com/inward/record.url?scp=84926101316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926101316&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2014.09.006

DO - 10.1016/j.ppedcard.2014.09.006

M3 - Article

AN - SCOPUS:84926101316

VL - 36

SP - 33

EP - 38

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1-2

ER -